USPTO Issues Two New Patents to XOMA
XOMA is engaged in the discovery and development of therapeutic antibodies. IL-1 beta is a pro-inflammatory cytokine recognized to be involved in the development of Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and other diseases.
The patents cover methods of treatment for Type 1 diabetes and certain cancers, including multiple myeloma, using XOMA 052 or other IL-1 beta antibodies with similar binding characteristics to XOMA 052.
US Patent 7,829,093 relates to methods of treating diabetes mellitus Type 1 with XOMA 052 or other IL-1 beta antibodies having similar binding properties.
The second patent, US 7,829,094, relates to methods of treating a cancer with XOMA 052 or other IL-1beta antibodies having similar binding properties, with the cancer being selected from multiple myeloma, acute myelogenous leukemia and chronic myelogenous leukemia. The patents provide coverage to 2026.
According to XOMA, three FDA-approved therapies that target the IL-1 pathway clinically validate the role of IL-1 in multiple diseases. These approved therapies and other IL-1 targeting drug candidates are in clinical development to address significant diseases including diabetes, cardiovascular disease, rheumatoid arthritis, gout and other inflammation-mediated diseases.
XOMA is conducting two Phase 2 clinical trials of XOMA 052 in patients with Type 2 diabetes and a Phase 2 trial in Type 1 diabetes. XOMA 052 also has demonstrated positive clinical benefit in a proof-of-concept trial for the treatment of vision-threatening uveitis of Behcet's disease.
Steven Engle, chairman and CEO of XOMA, said: “These patents bring the total number of issued U.S. and European patents from the XOMA 052 program to eight. We are succeeding in building a strong IP portfolio to protect our innovation around XOMA 052.”
Will the new patents benefit the company?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.